Merck & Co's two powerhouse oncology drugs – Keytruda and Lynparza – have failed to show efficacy when used in combination for patients with previously treated metastatic castration-resistant ...

When a pharma company says it is “providing an update” on a clinical trial the news is nearly always bad – and this week it was Merck & Co’s turn to issue a euphemistic press statement as ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act.

A new patent dispute is brewing between Halozyme Therapeutics (NASDAQ:HALO), a biotech focused on drug delivery technology, and Merck (NYSE:MRK) over an injectable version of the New Jersey-based ...

Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – pembrolizumab -, Merck’s anti-PD-1 therapy, for ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab).

Investors in Merck don't seem pleased with a competitor cancer-treatment candidate outperforming Keytruda. Summit Therapeutics says its monotherapy ivonescimab outperformed pembrolizumab, sold ...

>40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck MRK announced that the FDA has accepted its regulatory filing seeking approval for the subcutaneous (under the skin or SC) formulation of the blockbuster drug Keytruda (pembrolizumab). This ...